Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
Completed · Phase 1 · NCT02680184
Conditions: Melanoma
At a glance
- Research payments reported, 2025
- $31,902
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 199
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- CMP-001 (drug), Pembrolizumab (drug)
- Dates
- Started 2016-04-12; completion 2022-12-06
- Results posted
- Not yet
This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as monotherapy will be available to those who are currently being treated in either Part 1 or Part 2 of this study at the time of protocol Amendment 9…
From ClinicalTrials.gov, last updated 2025-07-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $31,902 in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Cancer Institute (nci) $27,500
- $4,402
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.